Company Information & Drug Savings for Bioverativ Therapeutics Inc. Medications
Bioverativ Therapeutics, now part of Sanofi, was a biopharmaceutical company focused on hemophilia treatments. The company developed ELOCTATE (efmoroctocog alfa) for hemophilia A and ALPROLIX (eftrenonacog alfa) for hemophilia B, extended half-life clotting factor therapies that reduce treatment burden for bleeding disorder patients. Sanofi continues advancing hemophilia care through Bioverativ’s innovative rare blood disorder research.
How to Contact Bioverativ Therapeutics Inc.
Phone
1-866-228-4625Medical Disclaimer
NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current. However, the knowledge and experience of a qualified healthcare professional should always be sought after instead of using the information on this page. Before taking any drug, you should always speak to your doctor or another qualified healthcare provider.
The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects. The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.
Experienced a Side Effect?
Report to Yellow Card (UK) or MedWatch (US)
